



# Knowledge Co-Creation Program (Group & Region Focus)

## GENERAL INFORMATION ON

### **Roles of Regulatory System and Pharmacists on Ensuring Proper Access to Quality Assured Medicines**

**課題別研修「適正な医薬品の供給・品質管理・使用に向けた  
薬事行政及び薬剤師の役割」**

**JFY 2017**

**NO. J17-04206 / ID. 1784415**

**Course Period in Japan: From June 28, 2017 to August 2, 2017**

This information pertains to one of the JICA Knowledge Co-Creation Program (Group & Region Focus) of the Japan International Cooperation Agency (JICA), which shall be implemented as part of the Official Development Assistance of the Government of Japan based on bilateral agreement between both Governments.

#### 'JICA Knowledge Co-Creation (KCC) Program' as a New Start

In the Development Cooperation Charter which is released from the Japanese Cabinet on February 2015, it is clearly pointed out that *"In its development cooperation, Japan has maintained the spirit of jointly creating things that suit partner countries while respecting ownership, intentions and intrinsic characteristics of the country concerned based on a field-oriented approach through dialogue and collaboration. It has also maintained the approach of building reciprocal relationships with developing countries in which both sides learn from each other and grow and develop together."* We believe that this 'Knowledge Co-Creation Program' will serve as a center of mutual learning process.

# ***I. Concept***

## **Background**

'Ensuring Proper Access to Quality Assured Medicines' is the essential element to strengthen health system, to improve the basic health services, and to realize universal health coverage (UHC).

However when a pharmaceutical regulatory system (authorization, post-marketing surveillance, inspection, etc.) is insufficient, there are many difficulties in implementing proper production and sales distribution. In such circumstances, the safety, efficacy and quality of medicine is not assured. Substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medicine is a prevalent example of the problem which may threat public health services. Therefore, it is one of the top priorities of the international cooperation to establish functional pharmaceutical regulatory systems in the world.

In this program, participants will learn 1) regulatory related systems on pharmaceuticals, 2) supply chain systems for quality assured medicines, and 3) role of pharmacist through lectures, and site-visits. Also, participants are expected to analyze the country's prioritized issues from each professions (administrators and pharmacists), and discuss the applicable measurements for improving proper access to quality medicines in their own countries.

## **For what?**

This program is intended to help participants' organization (national pharmaceutical regulatory authorities and/or tertiary level hospitals) to enhance its capacity for ensuring proper access to quality assured medicines.

## **For whom?**

This program is offered to the following (1) or (2);

- (1) Government officials who are engaged in making policies on pharmaceutical affairs and/or planning/implementation of pharmaceutical regulatory services, or
- (2) Senior pharmacists of tertiary level hospital, who are engaged in management of supply and rational use of medicines and human development. It is highly recommendable that he/she is a director of pharmaceutical department or equivalent, who has a responsibility of collaboration with national pharmaceutical regulatory authorities and its relevant agencies.

## **How?**

Participants shall have following opportunities in Japan to ensure program effectiveness.

1. Lectures on an overview of health system in Japan including pharmaceutical legislation and administration
2. Observations and site visits to local governments, pharmaceutical production companies, hospitals, research institute, and pharmacy
3. Discussions with Japanese/international experts and participants
4. Development and presentation of reports

## II. Description

- 1. Title (J-No.):** Roles of Regulatory System and Pharmacists on Ensuring Proper Access to Quality Assured Medicines (J17-04206)
- 2. Course Period in JAPAN:**  
June 28, 2017 to August 2, 2017
- 3. Target Regions or Countries :**  
Afghanistan, Brazil, Indonesia, Malawi, Moldova, Mongolia, Myanmar, Philippines, South Africa, Sri Lanka, Tanzania, Zambia
- 4. Eligible / Target Organization :**  
National pharmaceutical regulatory authorities and relevant agencies
- 5. Course Capacity (Upper limit of Participants) :**  
19 participants
- 6. Language to be used in this program :** English
- 7. Course Objective :**  
Participants summarize findings and applicable measurements for improving access to quality assured medicines in their own countries through better understanding of experiences in both Japan and participating countries.
- 8. Overall Goal:**  
Access to quality assured medicines will be improved in participating countries.
- 9. Expected Module Output and Contents:**  
This program consists of the following components. Details on each component are given below:

<b>(1) Preliminary Phase in a participant's home country:</b> June 2017 <i>Participating organization is required to prepare for the program in the respective country.</i>	
Expected Module Output	Activities
To formulate an Inception report	Current situation and issues on pharmaceutical regulatory services in participant's organization are preliminary identified. Submission due date: <u>June 14, 2017</u> (Guideline for the Inception Report will be sent at the time of notification of acceptance. )

**(2) Core Phase in Japan: June 28, 2017 to August 2, 2017**

*Participants dispatched by the organizations attend the Program implemented in Japan.*

Expected Module Output	Subjects/Agendas	Methodology
<p><u>Output module 1</u> To be able to understand and compare pharmaceutical regulatory system in the health service system of Japan and participating countries, as well as to understand trends of international collaboration among regulatory authorities.</p>	<ul style="list-style-type: none"><li>➤ Overview of pharmaceutical regulatory system in Japan (Legislation, Pharmaceutical approval system, Good Manufacturing Practices(GMP), Health insurance system and drug price listing, Safety measures, etc.),</li><li>➤ Inception report presentation and discussion</li></ul>	<p>-Lecture -Report presentation</p>
<p><u>Output module 2</u> To be able to understand regulatory management for access to quality medicines including inspection system.</p>	<ul style="list-style-type: none"><li>➤ Overlooking role of stakeholders to ensure quality-assured medicines (Activities by importers, manufacturing companies, wholesalers, hospitals and pharmacies),</li><li>➤ Pharmaceutical inspection system (Collaboration with local government, etc.),</li><li>➤ Trends in international cooperation among regulatory authorities</li></ul>	<p>-Lecture -Observation -Discussion</p>
<p><u>Output module 3</u> To be able to understand actual operations both in governmental and medical institutions for ensuring quality of medicines.</p> <p>(For administrators) Functions of local governments in regulatory system and quality management in manufacturers</p> <p>(For pharmacists) Roles of pharmacists in medical institutions and community and their education systems.</p>	<ul style="list-style-type: none"><li>➤ Field trip to Toyama prefecture (Local government, Pharmaceutical manufacturer and Pharmaceutical Research Institute)</li></ul> <p>(For administrators*)</p> <ul style="list-style-type: none"><li>➤ Observations at pharmaceutical companies, and pharmacy</li><li>➤ Lectures on countermeasures against counterfeit medicines.</li></ul> <p>(For pharmacists*)</p> <ul style="list-style-type: none"><li>➤ Observations and practical training at hospitals and pharmacies (Roles of pharmacists in wards and R&amp;D, Dispensing, Pharmaceutical products management, etc.),</li><li>➤ Education for pharmacists, Contribution of pharmacists to community</li></ul> <p>*Participants may be divided into 2 groups. (Please note that the programme is subject to change.)</p>	<p>-Field trip -Lecture -Observation -Discussion</p>

<p><u>Output module 4</u> To be able to clarify challenges from the view point of administrators and pharmacists in participants' workplace through sharing experiences and discussions.</p>	<ul style="list-style-type: none"> <li>➤ Summing-up discussion,</li> <li>➤ Feedback session of group programs,</li> <li>➤ Final report making and presentation</li> </ul>	<p>-Report development/ presentation -Workshop -Discussion</p>
--	---	--

**\*After returning home countries, participants are expected to share the final report within their supervisors and colleagues and discuss how to make use of results to their activities.**

### ***III. Conditions and Procedures for Application***

#### **1. Expectations from the Participating Organizations:**

- (1) This program is designed primarily for organizations that intend to address specific issues or problems identified in their operation. Participating organizations are expected to use the project for those specific purposes.
- (2) This program is enriched with contents and facilitation schemes specially developed in collaboration with relevant prominent organizations in Japan. These special features enable the project to meet specific requirements of applying organizations and effectively facilitate them toward solutions for the issues and problems.

#### **2. Nominee Qualifications:**

Applying Organizations are expected to select nominees who meet the following qualifications.

##### **(1) Essential Qualifications**

###### **1) Current Duties:**

who qualify (A) or (B) below;

(A) be a government officials who are engaged in making policies on pharmaceutical affairs and/or planning/implementation of pharmaceutical regulatory services, or

(B) be a senior pharmacists of tertiary level hospital, who is engaged in management of supply and rational use of medicines and human development. It is highly recommendable that he/she is a director of pharmaceutical department or equivalent, who has a responsibility of collaboration with national pharmaceutical regulatory authorities and its relevant agencies.

Note:

In the case two (2) seats are allocated to your country, a pair of above mentioned (A) and (B) is highly recommended.

###### **2) Occupational Qualification / Background:**

have more than 3 years' experience of the above-mentioned fields.

**3) Language:** Be proficient\* in spoken and written English which is equal to TOEFL iBT 79 or more (Since this course includes active participation into discussions, report development and presentation, high English competency is required. If applicants have official certification of English language e.g. TOEFL, TOEIC etc, please attach it for selection purpose).

\*Conversational accuracy & fluency in wide range of situations: discussions, short presentations & interviews. Compound complex sentences. Extended essay formation.

4) **Health:** must be in good health, both physically and mentally, to participate in the Program in Japan. Pregnant applicants are not recommended to apply due to the potential risk of health and life issues of mother and fetus.

##### **(2) Recommendable Qualifications**

- 1) Age: be under fifty (50) years of age (when applying)

### 3. Required Documents for Application :

(1) **Application Form:** The Application Form is available at **the JICA office (or the Embassy of Japan)**.

(2) **Photocopy of passport:** to be submitted with the application form, if you possess your passport which you will carry when entering Japan for this program. If not, you are requested to submit its photocopy as soon as you obtain it.

\*Photocopy should include the followings:

Name, Date of birth, Nationality, Sex, Passport number and Expire date.

(3) **Nominee's English Score Sheet:** to be submitted with the application form. If you have any official documentation of English ability. (e.g., TOEFL, TOEIC, IELTS)

### 4. Procedures for Application and Selection :

#### (1) Submission of the Application Documents:

Closing date for applications: **Please inquire to the JICA office (or the Embassy of Japan)**.

(After receiving applications, the JICA office (or the Embassy of Japan) will send them to **the JICA Center in JAPAN** by **April 28, 2017**.)

#### (2) Selection:

After receiving the documents through proper channels from your government, the JICA office (or the embassy of Japan) will conduct screenings, and then forward the documents to the JICA Center in Japan. Selection will be made by the JICA Center in consultation with concerned organizations in Japan. *The applying organization with the best intention to utilize the opportunity of this program will be highly valued in the selection.* Qualifications of applicants who belong to the military or other military-related organizations and/or who are enlisted in the military will be examined by the Government of Japan on a case-by-case basis, consistent with the Development Cooperation Charter of Japan, taking into consideration their duties, positions in the organization, and other relevant information in a comprehensive manner.

#### (3) Notice of Acceptance:

Notification of results will be made by the JICA office (or the Embassy of Japan) **not later than May 30, 2017**.

### 5. Document(s) to be submitted by accepted candidates:

#### (1) Inception Report -- to be submitted by **June 14, 2017**

Before coming to Japan, only accepted candidates are required to prepare an Inception Report. Detailed information on the guideline for the "Inception Report" will be provided to the participant upon notification of the acceptance to the program.

#### (2) Medical History on Infectious Diseases/ Vaccinations/ Antibody test -- to be submitted by **June 9, 2017**.

Please refer to the "V. Annex: Other Information" for detailed explanation.

## **6. Conditions for Attendance:**

- (1)** to strictly adhere to the program schedule.
- (2)** not to change the program topics.
- (3)** not to extend the period of stay in Japan.
- (4)** not to be accompanied by family members during the program.
- (5)** to return to home countries at the end of the program in accordance with the travel schedule designated by JICA.
- (6)** to refrain from engaging in any political activities, or any form of employment for profit or gain.
- (7)** to observe Japanese laws and ordinances. If there is any violation of said laws and ordinances, participants may be required to return part or all of the training expenditure depending on the severity of said violation.
- (8)** to observe the rules and regulations of the accommodation and not to change the accommodation designated by JICA.



## IV. Administrative Arrangements

### 1. Organizer:

(1) **Name:** JICA TOKYO, Human Development Division

(2) **Contact:** Ms. Naho AIZU ([ticthd@jica.go.jp](mailto:ticthd@jica.go.jp))

### 2. Implementing Partner:

(1) **Name:** Japan International Corporation of Welfare Services (JICWELS)

(2) **URL:**

<http://www.jicwels.or.jp/files/2013E5B9B4JICWELSEFBE8AEFBE9FEFBE9DEFBE8CEFBE9AEFB.pdf>

(3) **Contact:** Ms.Hiroko FUJIMORI ([jigyo@jicwels.or.jp](mailto:jigyo@jicwels.or.jp))

### 3. Travel to Japan:

(1) **Air Ticket:** The cost of a round-trip ticket between an international airport designated by JICA and Japan will be borne by JICA.

(2) **Travel Insurance:** Coverage is from time of arrival up to departure in Japan. Thus traveling time outside Japan will not be covered.

### 4. Accommodation in Japan:

JICA will arrange the following accommodations for the participants in Japan:

JICA Tokyo International Center (JICA TOKYO)

Address: 2-49-5 Nishihara, Shibuya-ku, Tokyo 151-0066, Japan

TEL: 81-3-3485-7051 FAX: 81-3-3485-7904

(where “81” is the country code for Japan, and “3” is the local area code)

If there is no vacancy at JICA TOKYO, JICA will arrange alternative accommodations for the participants. Please refer to facility guide of TIC at its URL,

<Service Guide>

[http://www.jica.go.jp/english/about/organization/domestic/c8h0vm0000023sgf-att/tokyo\\_service.pdf](http://www.jica.go.jp/english/about/organization/domestic/c8h0vm0000023sgf-att/tokyo_service.pdf)

<Facility Guide>

[http://www.jica.go.jp/english/about/organization/domestic/c8h0vm0000023sgf-att/tokyo\\_facilities.pdf](http://www.jica.go.jp/english/about/organization/domestic/c8h0vm0000023sgf-att/tokyo_facilities.pdf)

<JICA Tokyo’s Facebook Page>

<https://www.facebook.com/jicatokyo>

### 5. Expenses:

The following expenses will be provided for the participants by JICA:

(1) Allowances for accommodation, meals, living expenses, outfit, and shipping

(2) Expenses for study tours (basically in the form of train tickets.)

(3) Free medical care for participants who become ill after arriving in Japan (costs related to pre-existing illness, pregnancy, or dental treatment are not included)

(4) Expenses for program implementation, including materials

For more details, please see “III. ALLOWANCES” of the brochure for participants titled “KENSU-IN GUIDE BOOK,” which will be given before departure for Japan.

### 6. Pre-departure Orientation:

A pre-departure orientation will be held at the respective country’s JICA office (or Japanese Embassy), to provide participants with details on travel to Japan, conditions of the workshop, and other matters.

## **V. ANNEX: Other Information**

**For accepted participants**

**Participants are requested to prepare/bring the following;**

1. Personal Computer

Personal computer equipped with “Word” and “Power point”, if you have one. A PC is necessary for preparation of reports and / or power point presentations. If there are some compelling reasons for not bringing a PC, please e-mail below **by June 9, 2017**. We will lend you a PC from the beginning of the program in Japan. Please note, however, if you fail to inform us by the above date, it will take at least one week after your arrival to lend a PC (till then, you will be able to use a computer in our common PC room at JICA Tokyo).

2. White Coat (Uniform)

Since this program includes medical institute visits, it is recommended to bring your own white coat (uniform), if you possess them.

3. Medical History on Infectious Diseases/ Vaccinations/ Antibody test

Since this program schedules hospital visit, you are kindly requested to fill out the following list and submit to JICA **by June 9, 2017**.

It is possible that the hospital oblige participants to take countermeasures against 4 kinds of infectious diseases (Measles, Rubella, Chickenpox, and Mumps). This is necessary not only for protecting health staffs from the exposure to infection but also for preventing them from being infection source.

**List of Vaccination History**

Infectious Diseases	History *Please check <input checked="" type="checkbox"/> where appropriate.	Vaccinations (Immunization)		Result of antibody test
		Vaccinated	Date(D/M/Y)	
Measles	<input type="checkbox"/> Never infected <input type="checkbox"/> Infected (    years old) <input type="checkbox"/> Unknown	<input type="checkbox"/> Yes <input type="checkbox"/> No		Date of test: (day/month/year)
				Results : <input type="checkbox"/> positive <input type="checkbox"/> false-positive <input type="checkbox"/> negative <input type="checkbox"/> unclear
				Remarks:
Rubella	<input type="checkbox"/> Never infected <input type="checkbox"/> Infected (    years old) <input type="checkbox"/> Unknown	<input type="checkbox"/> Yes <input type="checkbox"/> No		Date of test: (day/month/year)
				Results : <input type="checkbox"/> positive <input type="checkbox"/> false-positive <input type="checkbox"/> negative <input type="checkbox"/> unclear
				Remarks:
Chicken Pox	<input type="checkbox"/> Never infected <input type="checkbox"/> Infected (    years old) <input type="checkbox"/> Unknown	<input type="checkbox"/> Yes <input type="checkbox"/> No		Date of test: (day/month/year)
				Results : <input type="checkbox"/> positive <input type="checkbox"/> false-positive <input type="checkbox"/> negative <input type="checkbox"/> unclear
				Remarks:
Mumps	<input type="checkbox"/> Never infected <input type="checkbox"/> Infected (    years old) <input type="checkbox"/> Unknown	<input type="checkbox"/> Yes <input type="checkbox"/> No		Date of test: (day/month/year)
				Results : <input type="checkbox"/> positive <input type="checkbox"/> false-positive <input type="checkbox"/> negative <input type="checkbox"/> unclear
				Remarks:

E-mail Title	<b>J17-04206</b> “Roles of Regulatory Systems and Pharmacists on Ensuring Proper Access to Quality Assured Medicines”
E-mail address	ticthd@jica.go.jp

## ***For Your Reference***

### **JICA and Capacity Development**

The key concept underpinning JICA operations since its establishment in 1974 has been the conviction that “capacity development” is central to the socioeconomic development of any country, regardless of the specific operational scheme one may be undertaking, i.e. expert assignments, development projects, development study projects, training programs, JOCV programs, etc.

Within this wide range of programs, Training Programs have long occupied an important place in JICA operations. Conducted in Japan, they provide partner countries with opportunities to acquire practical knowledge accumulated in Japanese society. Participants dispatched by partner countries might find useful knowledge and re-create their own knowledge for enhancement of their own capacity or that of the organization and society to which they belong.

About 460 pre-organized programs cover a wide range of professional fields, ranging from education, health, infrastructure, energy, trade and finance, to agriculture, rural development, gender mainstreaming, and environmental protection. A variety of programs are being customized to address the specific needs of different target organizations, such as policy-making organizations, service provision organizations, as well as research and academic institutions. Some programs are organized to target a certain group of countries with similar developmental challenges.

### **Japanese Development Experience**

Japan was the first non-Western country to successfully modernize its society and industrialize its economy. At the core of this process, which started more than 140 years ago, was the “*adopt and adapt*” concept by which a wide range of appropriate skills and knowledge have been imported from developed countries; these skills and knowledge have been adapted and/or improved using local skills, knowledge and initiatives. They finally became internalized in Japanese society to suit its local needs and conditions.

From engineering technology to production management methods, most of the know-how that has enabled Japan to become what it is today has emanated from this “*adoption and adaptation*” process, which, of course, has been accompanied by countless failures and errors behind the success stories. We presume that such experiences, both successful and unsuccessful, will be useful to our partners who are trying to address the challenges currently faced by developing countries.

However, it is rather challenging to share with our partners this whole body of Japan’s developmental experience. This difficulty has to do, in part, with the challenge of explaining a body of “tacit knowledge,” a type of knowledge that cannot fully be expressed in words or numbers. Adding to this difficulty are the social and cultural systems of Japan that vastly differ from those of other Western industrialized countries, and hence still remain unfamiliar to many partner countries. Simply stated, coming to Japan might be one way of overcoming such a cultural gap.

JICA, therefore, would like to invite as many leaders of partner countries as possible to come and visit us, to mingle with the Japanese people, and witness the advantages as well as the disadvantages of Japanese systems, so that integration of their findings might help them reach their developmental objectives.



***CORRESPONDENCE***

For enquiries and further information, please contact the JICA office or the Embassy of Japan. Further, address correspondence to:

**JICA Tokyo International Center (JICA TOKYO)**  
**Address: 2-49-5 Nishihara, Shibuya-ku, Tokyo 151-0066, Japan**  
TEL: +81-3-3485-7051 FAX: +81-3-3485-7904